Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Nemaura Medical sells 1.59M shares at $7.25 in 'best efforts' offering » 09:33
07/28/20
07/28
09:33
07/28/20
09:33
NMRD

Nemaura Medical

$9.26 /

+0.175 (+1.93%)

Nemaura Medical announced…

Nemaura Medical announced the pricing of a "best efforts" public offering of an aggregate of up to 1,586,206 shares of its common stock and warrants to purchase up to an aggregate of 793,103 shares of its common stock. Each share of common stock and accompanying one-half of a warrant is being sold for a combined purchase price of $7.25, for a gross deal size of $11.5M. The offering is expected to close on or about July 30. The company further announced that the press release issued on July 27 regarding a proposed public offering was issued in error because the offering has taken the form of a "best efforts" and not an "underwritten" public offering. Each whole warrant will have an exercise price of $8.00 per share and is exercisable immediately. The warrants will expire five years from the date of issuance. Kingswood Capital Markets, a division of Benchmark Investments, is acting as the sole placement agent in connection with the offering.

ShowHide Related Items >><<
NMRD Nemaura Medical
$9.26 /

+0.175 (+1.93%)

Syndicate
Nemaura Medical offers to sell common stock, no amount given  19:32
07/27/20
07/27
19:32
07/27/20
19:32
NMRD

Nemaura Medical

$9.26 /

+0.175 (+1.93%)

 
ShowHide Related Items >><<
NMRD Nemaura Medical
$9.26 /

+0.175 (+1.93%)

Hot Stocks
Nemaura Medical enters LOI to acquire Healthimation to augment proBEAT launch » 11:01
07/27/20
07/27
11:01
07/27/20
11:01
NMRD

Nemaura Medical

$9.88 /

+0.795 (+8.75%)

Nemaura Medical announced…

Nemaura Medical announced it has entered into a letter of intent with Healthimation, LLC relating to a possible acquisition of the Healthimation business by Nemaura. Nemaura entered into the letter of intent to augment and fast-track its foray into the U.S. and other global territories with its proBEAT product offering.

ShowHide Related Items >><<
NMRD Nemaura Medical
$9.88 /

+0.795 (+8.75%)

Hot Stocks
Nemaura Medical evaluates new applications for CLM using BEAT platform » 07:29
07/14/20
07/14
07:29
07/14/20
07:29
NMRD

Nemaura Medical

$8.16 /

+0.36 (+4.62%)

Nemaura Medical issued a…

Nemaura Medical issued a presentation outlining potential new applications for monitoring disease progression in Covid-19 patients using Continuous Lactate Monitoring, or CLM. Nemaura Medical said in a release, "The Company has previously discussed the market for athletic performance monitoring using its non-invasive CLM, and based on recently published independent clinical evaluations, the measurement of blood lactic acid has been established as an indicator for disease progression in Covid-19 patients. Both the CGM and CLM products are based on Nemaura's BEAT platform, which is designed to non-invasively extract a number of analytes through the skin. By adapting the sensor chemistry, algorithm and mobile app interface initially developed for sugarBEAT, the BEAT platform has the potential to be utilized for several markets beyond glucose monitoring and diabetes. Nemaura is evaluating the timelines for bringing the CLM to market as a Class 2 approved Medical Device."

ShowHide Related Items >><<
NMRD Nemaura Medical
$8.16 /

+0.36 (+4.62%)

Hot Stocks
Nemaura Medical evaluates new applications for CLM using BEAT platform » 07:13
07/14/20
07/14
07:13
07/14/20
07:13
NMRD

Nemaura Medical

$8.16 /

+0.36 (+4.62%)

Nemaura Medical issued a…

Nemaura Medical issued a presentation outlining potential new applications for monitoring disease progression in Covid-19 patients using Continuous Lactate Monitoring, or CLM. Nemaura Medical said in a release, "The Company has previously discussed the market for athletic performance monitoring using its non-invasive CLM, and based on recently published independent clinical evaluations, the measurement of blood lactic acid has been established as an indicator for disease progression in Covid-19 patients. Both the CGM and CLM products are based on Nemaura's BEAT platform, which is designed to non-invasively extract a number of analytes through the skin. By adapting the sensor chemistry, algorithm and mobile app interface initially developed for sugarBEAT, the BEAT platform has the potential to be utilized for several markets beyond glucose monitoring and diabetes. Nemaura is evaluating the timelines for bringing the CLM to market as a Class 2 approved Medical Device."

ShowHide Related Items >><<
NMRD Nemaura Medical
$8.16 /

+0.36 (+4.62%)

Conference/Events
Nemaura Medical participates in a webinar with RedChip Companies » 10:50
07/07/20
07/07
10:50
07/07/20
10:50
NMRD

Nemaura Medical

$8.81 /

+0.415 (+4.94%)

A webinar to provide an…

A webinar to provide an update on Nemaura Medical's developments including commercialization progress, US product launch, and status of collaborative partnerships, as well as an update on a continuous temperature monitor (CTM) for the diabetes and non-diabetes markets will be held on July 7 at 11 am hosted by RedChip. Webcast Link

ShowHide Related Items >><<
NMRD Nemaura Medical
$8.81 /

+0.415 (+4.94%)

Conference/Events
Nemaura Medical participates in a webinar with RedChip Companies » 08:59
07/07/20
07/07
08:59
07/07/20
08:59
NMRD

Nemaura Medical

$8.40 /

+0.07 (+0.84%)

A webinar to provide an…

A webinar to provide an update on Nemaura Medical's developments including commercialization progress, US product launch, and status of collaborative partnerships, as well as an update on a continuous temperature monitor (CTM) for the diabetes and non-diabetes markets will be held on July 7 at 11 am hosted by RedChip. Webcast Link

ShowHide Related Items >><<
NMRD Nemaura Medical
$8.40 /

+0.07 (+0.84%)

Hot Stocks
Nemaura Medical submits PMA application for sugarBEAT to U.S. FDA » 06:02
07/07/20
07/07
06:02
07/07/20
06:02
NMRD

Nemaura Medical

$8.40 /

+0.07 (+0.84%)

Nemaura Medical together…

Nemaura Medical together with BEATdiabetes, announced it has submitted its PMA application for sugarBEAT to the United States FDA through the eCopy program submission process. The intended use of sugarBEAT is for persons with diabetes as an adjunct to finger prick testing to monitor and track their glucose profiles, so that the user can be better informed about the factors affecting their glucose profile, and to help manage their diabetes or potentially reverse their diabetes in the case of Type 2 diabetes. sugarBEAT is targeted initially at the Type 2 diabetic population, which number is greater than 25M people in the U.S.

ShowHide Related Items >><<
NMRD Nemaura Medical
$8.40 /

+0.07 (+0.84%)

Over a month ago
Hot Stocks
Nemaura Medical Inc trading resumes  10:01
06/16/20
06/16
10:01
06/16/20
10:01
NMRD

Nemaura Medical

$12.00 /

+1.6 (+15.38%)

 
ShowHide Related Items >><<
NMRD Nemaura Medical
$12.00 /

+1.6 (+15.38%)

Hot Stocks
Nemaura Medical Inc trading halted, volatility trading pause  09:56
06/16/20
06/16
09:56
06/16/20
09:56
NMRD

Nemaura Medical

$11.51 /

+1.11 (+10.67%)

 
ShowHide Related Items >><<
NMRD Nemaura Medical
$11.51 /

+1.11 (+10.67%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.